Background: In the modern era of chemotherapy, the outcome of pediatric non-Hodgkin lymphoma (NHL) continues to improve internationally. Limited data such as information on epidemiology and survival, however, are available in Asian countries. Methods: Children (≤15 years old) diagnosed with histologically proven NHL from 1998 to 2014 were retrospectively analyzed.
Non-Hodgkin lymphoma (NHL) is the third most common malignancy in children and adolescents in Europe and the USA. [1] [2] [3] A recent study by the Thai Pediatric Oncology Group found that NHL is the second most common malignancy in children after leukemia and accounts for 6.4 per million cases. 4 Burkitt lymphoma (BL) constitutes 50% of pediatric NHL, 5 diffuse large B-cell lymphoma (DLBCL) constitutes 10-20%, 5, 6 lymphoblastic lymphoma (LBL) constitutes 20%, and large cell lymphoma (LCL) constitutes 10%. 3, 5, 7 Peripheral T-cell lymphoma (PTCL) is a rare and less accurately defined subtype of childhood NHL for which optimal treatment is not yet established.
During the past three decades, the outcome of pediatric NHL has been tremendously improved. [8] [9] [10] In Europe, the 5 year survival rate increased from 56% in the 1970s to 82% between 1995 and 2002. 10 This may be the result of improvements in diagnostic procedures, therapeutic strategies and supportive care that does not involve new medication. The situation, however, is not always as encouraging in the developing world.
Only limited data on pediatric NHL have been available in Thailand compared with developed countries. The purposes of this study were to evaluate the demographic data in pediatric NHL and to assess the effects of our treatment stratification on the survival of childhood NHL at our research university hospital in Thailand.
Methods

Patients
In this single-institution retrospective study, we enrolled pediatric patients aged ≤15 years who had been diagnosed with NHL between January 1998 and December 2014 and followed up with treatment until 31 January 2016. Our institute, Ramathibodi Hospital (RAMA), is a tertiary-care referral center and serves as the research center for Mahidol University in Thailand. The Institutional Ethics Committee, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, approved this study. Diagnosis was made on tissue biopsy, cerebrospinal fluid (CSF) or effusion analyses, and bone marrow (BM) aspiration and/or biopsy specimens. Because there is considerably less heterogeneity of pediatric NHL than adult NHL, not all categories of the World Health Organization (WHO) classification pertain to pediatric NHL. All patients were classified into five subtypes based on the major histopathological characteristics: BL, LBL, LCL, DLBCL, and PTCL. Clinical staging of BL, LBL, LCL, and DLBCL was based on the St Jude staging system, 11 and clinical staging of PTCL was based on type and extent of skin involvement, the presence of palpable lymph node involvement, and the presence of visceral disease according to the tumor, nodes, metastasis (TNM) staging system (Table 1) . Pretreatment clinical data were collected for each patient, including age; sex; complete blood count; lactate dehydrogenase (LDH) concentration; date of diagnosis; pathological diagnosis; radiological investigations (chest roentgenography, abdominal sonography, bone scintigraphy, and computed tomography [CT] or magnetic resonance imaging); lumbar puncture; date of disease progression, relapse, or death; date of last follow up; and clinical outcome. In patients with BM and/or central nervous system (CNS) involvement, serial BM aspiration and/or lumbar puncture was carried out until the patients were free of lymphoma cells. The tumor response was evaluated after the second course of treatment. Complete remission (CR) was defined as the clinical disappearance of disease on CT scan, BM examination, and/or CSF analysis. Partial response (PR) was defined as tumor shrinkage >50%. Progressive disease was defined as evidence of disease or tumor regrowth during treatment. Relapse was defined as the reappearance of disease after 1 month of CR. Chemotherapy-and lymphoma-related complications and documented infection during grade 3 or 4 neutropenia (according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0) that occurred during treatment were recorded.
Stratification of treatment and chemotherapy
The treatment scheme was stratified according to the histopathological subgroup and stage (Fig. 1) . Stage I and II LBL was treated with cyclophosphamide (CTX), doxorubicin, vincristine, and prednisolone (CHOP) for six cycles with an additional 6 months of mercaptopurine and methotrexate (MTX). Patients with stage III and IV LBL received the modified St Jude TOTAL-XV protocol (RAMA-ALL protocol) for childhood acute lymphoblastic leukemia (ALL), while those with LCL and PTCL received the RAMA-LCL protocol consisting of alternate cycles of CTX, etoposide, dexamethasone, high-dose MTX and cytarabine, carboplatin, dexamethasone, and high-dose MTX. The modified Lymphome Malin B 89 (LMB-89) protocol 12 was used in patients with BL. From 1998 to 2002, patients with DLBCL received the RAMA-LCL protocol and had high relapse rates. After interim evaluation of the treatment stratification, we changed the treatment regimen for DLBCL to a modified LMB protocol. All protocols are listed in Table S1 .
All patients received co-trimoxazole twice daily for 3 consecutive days per week as prophylaxis for Pneumocystis carinii infection. No prophylactic antibiotics were used. Antifungal prophylaxis was given only in cases of recurrent fungal infection.
Statistical analysis
The event-free survival (EFS) rate was determined as the time from the date of diagnosis to the first event (disease progression, relapse, death from any cause, or the most recent follow up). The overall survival (OS) rate was calculated from the Table 2 . Most patients were male (65.8%) with a median age of 10.12 years (range, 1.83-15.00 years). A total of 71.9% of patients had advanced disease (stage III and IV) at diagnosis. The distribution of NHL subtypes across different age groups is shown in Figure 2 . Of the 114 patients, 98 (86%) achieved CR, eight (7%) had progressive disease, and eight (7%) died during induction chemotherapy because of either infection (six patients) or treatment-related complications (two patients with massive gastrointestinal bleeding). Six patients with progressive disease subsequently died during re-induction chemotherapy, while two patients with progressive DLBCL survived after autologous hematopoietic stem cell transplantation (auto-HSCT). Treatment-related toxicity occurred in 17 patients (14.9%). Eight of 17 patients developed acute kidney injury, which was successfully managed by intensive hydration and supportive care. Other treatment-related toxicities included drug-induced hepatitis, acute pancreatitis, bleeding, hyperglycemic ketoacidosis, and methotrexate-induced neurotoxicity, and most of these spontaneously recovered. Documented infections during grade 3 or 4 neutropenia occurred at any time during treatment in 25 patients (21.9%). Of these, microbiologic cultures were positive in 23.2% of all febrile neutropenic episodes. The infection-related mortality rate was 5.3%. The three most common organisms from blood isolates were Pseudomonas aeruginosa, Escherichia coli, and coagulase-negative Staphylococcus spp.
Regardless of the histopathological subtypes, the KaplanMeier 5 year EFS and 5 year OS rates were 71.5% AE 4.3% and 74.8% AE 4.1%, respectively ( Fig. 3a) with a median follow up of 78.4 months (range, 0.37-261.57 months). According to the histopathological subtypes, the Kaplan-Meier 5 year EFS and 5 year OS rates were 88.5% AE 6.3% and 88.5% AE 6.3% for BL' 60.6% AE 10.3% and 69.1% AE 9.7% for DLBCL; 74.8% AE 8.9% and 78.6% AE 8.5% for LBL; 65.2% AE 9.9% and 64.9% AE 10.0% for LCL; and 65.5% AE 11.5% and 71.1% AE 10.8% for PTCL, respectively (Fig. 3b) . Patients with an advanced stage at presentation had significantly lower 5 year EFS and OS rates than those with a localized stage (stage I and II; 66.5% AE 5.3% and 70.2% AE 5.1% for advanced stage; and 84.0% AE 6.6% and 86.4% AE 6.4% for localized stage, respectively; P = 0.042 and 0.046, respectively, log-rank test). The Kaplan-Meier EFS according to Pseudomonas aeruginosa, n = 2; candidemia, n = 1; typhlitis, n = 1; and pneumonia without a documented organism, n = 2.
§ Massive upper gastrointestinal bleeding, n = 2; hemoptysis, n = 1. ¶ Drug-induced hepatitis, massive upper gastrointestinal bleeding, drug-induced diabetic ketoacidosis, methotrexate-induced neurotoxicity, pulmonary hemorrhage.
† † Tumor lysis syndrome, lymphoma-associated hemophagocytic syndrome, symptomatic localization-related epilepsy, obstructive nephropathy with acute renal insufficiency, chronic renal failure, cytomegalovirus retinitis, cytomegalovirus reactivation.
‡ ‡ Documented infection with grade 3 or 4 neutropenia (National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0) at any time during treatment. disease stage is shown in Figure 4a . According to the age at diagnosis, patients aged <10 years tended to have a better 5 year OS rate than those aged >10 years (81.7% AE 5.3% vs 68.0% AE 6.3%, respectively; P = 0.159, log-rank test; Fig. 4b ). The presence of B symptoms (i.e. systemic symptoms of fever, night sweats, and weight loss that can be associated with both Hodgkin's lymphoma and non-Hodgkin's lymphoma) had a significant negative impact on the 5 year EFS rate (presence, 67.0% AE 6.2% vs absence, 81.1% AE 5.2%; P = 0.03). There was no association of clinical phenotype variables such as sex, initial hemoglobin, serum albumin, LDH concentration, BM or CNS involvement with the 5 year EFS and OS rates. A highly elevated serum LDH concentration of 13 504 IU/L was found in one patient with stage IV BL who still survived. Median LDH concentration at diagnosis was 351.5 IU/L (range, 126-13 504 IU/L).
Subgroup-directed treatment protocols
Burkitt lymphoma
Twenty patients (76.9%) with BL were male with a median age at diagnosis of 5.14 years (range, 2.5-15.0 years). The primary tumor sites were the abdomen in 10 patients (38.5%) and head and neck in 10 patients (38.5%). BM and CNS involvement were found in five patients (19.2%) and one patient (3.8%), respectively. The patients with BM involvement also had CNS involvement. Six patients had stage I disease, five had stage II, 10 had stage III, and five had stage IV. LDH concentration was >500 IU/L in 11 patients (42.3%) but was not correlated with either the 5 year EFS or 5 year OS rate. CR was achieved in 92.3% of patients. During induction chemotherapy, one patient developed progressive disease and died, and another patient developed Pseudomonas aeruginosa septicemia and died. Another patient, who had stage III disease, developed BM relapse in the 3 months following remission and subsequently died of progressive disease 43 days after match-related allogeneic HSCT.
Diffuse large B-cell lymphoma
Seventeen patients (73.9%) with DLBCL were male with a median age at diagnosis of 10.3 years (range, 1.8-14.8 years). Twenty-two patients (95.7%) presented with advanced disease with a high incidence of CNS involvement (43.5% of patients with stage IV disease). Seven patients presented with neurological symptoms: three of them had facial palsy, two had hemiparesis, one had strabismus, and one had paraparesis. Four patients (17.4%) presented with bone pain, four (17.4%) with an abdominal mass, four (17.4%) with a head and neck mass, three (13%) with a mediastinal mass, and one (4.3%) with a testicular mass. Six patients (26%) did not achieve CR; three of these six patients died during treatment of progressive disease. Another three patients underwent auto-HSCT; two were still in remission for up to 5 years after transplant, and one died of relapsed disease after auto-HSCT. Another two patients died of overwhelming infection during treatment, and one died of an unknown cause. According to the assigned treatment protocol, five of six patients who received the RAMA-LCL protocol did not achieve CR. Based on these results, a modified LMB protocol was applied to the treatment of patients with DLBCL with a subsequently lower rate of relapse (11.8%). According to the treatment protocol, the 5 year EFS for patients treated with modified LMB protocol was significantly higher than that in patients treated with the RAMA-LCL protocol (76.5% AE 10.3% and 16.7% AE 15.2%, respectively; P = 0.008). The 5 year OS rates for patients treated with the modified LMB protocol and LCL protocol were 76.5% AE 10.3% and 50.0% AE 20.4%, respectively (P = 0.29).
Lymphoblastic lymphoma
Of the patients with LBL, 14 (58.3%) were male and the median age at diagnosis was 8.5 years (range, 1.9-14.8 years). The most common initial symptoms were a head and neck mass (33.3%), prolonged fever (20.8%), and dyspnea (16.7%).
Thirteen patients (54.2%) had a mediastinal mass at diagnosis. Two patients had stage I disease, five had stage II, 11 had stage III, and six had stage IV. CR was achieved in all patients. Six patients (25%) developed disease relapse after achieving CR. Of these six patients, five (83.3%) died: two with bulky disease developed progressive disease and died during treatment; one with stage II disease developed BM relapse in the 6 months after completion of the CHOP protocol, declined treatment after re-induction chemotherapy, and subsequently died at home; one with stage III disease developed sudden hemoptysis during the 50th week of the maintenance phase of the RAMA-ALL protocol and subsequently died at home; and one died of an unknown cause 2 years after completion of treatment. Only one patient with stage II disease relapsed 8 months after completion of the CHOP protocol and survived for >10 years after being successfully treated with the RAMA-ALL protocol without HSCT.
Large cell lymphoma
Twenty-three patients were diagnosed with LCL. Of these, 16 patients (69.6%) were male with a median age of 11.8 years (range, 2.2-14.9 years). Overall, 39.1% of patients presented with prolonged fever with a median time to diagnosis of 7 weeks. Eight patients (34.8%) had abdominal involvement, seven (30.4%) had cutaneous involvement, six (26.1%) had generalized lymphadenopathy, and one (4.3%) had CNS involvement. Most patients (73.9%) presented with advanced disease and tended to have a lower 5 year EFS rate than patients with localized disease (83.3% AE 15.2% vs 58.8% AE 11.9%, respectively; P = 0.21). Nine patients (39.1%) died. Two had stage IV LCL and developed lymphoma-associated hemophagocytic syndrome; both died during their second course of treatment. Four patients relapsed after completion of treatment, and all died during subsequent treatment of the relapsed disease. Two patients died of overwhelming infection during induction chemotherapy. Another patient died of massive upper gastrointestinal bleeding.
Peripheral T-cell lymphoma
Eighteen patients were diagnosed with PTCL, not otherwise specified according to the WHO classification. No patients had other types such as extranodal natural killer (NK)/T cell lymphoma, nasal type, or hepatosplenic T-cell lymphoma. Eight patients were male with a median age of 11.4 years (range, 3.2-14.9 years). Sixty-one percent of patients presented with advanced disease. A skin mass was present in 77.8% of patients as a presenting symptom, accompanied by subacute fever. Two patients presented with other cutaneous lesions (erythema multiforme and hydroa vacciniforme, respectively). Another two patients presented with malaise and prolonged fever without localizing signs. According to the TNM staging system, six patients had stage I disease, one had stage II, five had stage III, and six had stage IV. After treatment with the RAMA-LCL protocol, CR was achieved in 15 patients (83.3%) with subsequent relapse in four. One patient who did not achieve CR subsequently died of progressive disease. Another two patients with stage IV disease died before the evaluation of remission because of intractable candidemia and severe disseminated intravascular coagulation with massive upper gastrointestinal bleeding, respectively. Five patients (83%) of those with stage IV disease died of either relapsed disease or treatment-related complications. A total of five patients relapsed: two of them underwent auto-HSCT and survived, and the remaining three died of progressive disease during treatment of their relapse.
Discussion
Non-Hodgkin lymphoma is the third most common childhood malignancy, with good long-term survival even in patients with advanced disease. 4, 9 While excellent findings have been mainly reported in developed nations, developing countries are experiencing lower survival rates. The present study was based on prospective recording of the initial characteristics and longterm follow up of 114 patients with NHL during a 17 year period, and demonstrated the strength of the treatment approach in terms of optimal management of childhood NHL in a tertiary-care institute in Thailand. Most of the present patients had advanced-stage high-grade lymphoma. We observed a male preponderance, with a male : female ratio of 2:1, which is consistent with reports from other series. BL was the most common type of NHL in pre-adolescent children, while there was a higher incidence of DLBCL and LCL in adolescents. This age distribution of NHL subtypes across age groups correlates with that in previous studies. 5, 13, 14 Different distributions of each of the NHL subtypes from Western countries, however, have been reported, with a higher incidence of PTCL in the present cohort. In 2005, Burkhardt et al.
reported that BL and Burkitt leukemia accounted for 48.2% of childhood NHL in Germany, 5 while only 22.8% of patients had BL in the present study. Additionally, no patients in the present cohort had primary mediastinal B-cell lymphoma or follicular lymphoma, which are important NHL subtypes found in older adolescents and young adults. This might be due to selection bias because patients aged >15 years were treated with protocols established by hematologists who treat adult patients. Asian adults have a relatively high incidence of NK/T-cell lymphomas compared with adults from Western countries. [15] [16] [17] [18] The prevalence of PTCL in the present study was uniquely high (15.8%) compared with that in previous studies (1.6-10.0%). The present results correlated with those noted by Sukpanichnant, who found that PTCL accounted for 25.8% of malignant lymphomas in children and adults in Thailand. 19 Conversely, PTCL, unspecified accounted for 6.3% of malignant lymphomas in children and adults in Korea. 18 Genetic and environmental factors might explain these significant differences between different geographic regions. An advanced disease stage and the presence of B symptoms at diagnosis were significant poor prognostic factors determining the 5 year EFS rate for the overall cohort of patients with NHL in this study. There was no significant difference in 5 year EFS according to age, sex, or LDH concentration, with a tendency toward a higher 5 year OS in patients aged <10 years at diagnosis. This might be related to the NHL subtype and age at diagnosis: patients with BL and LBL were younger and had higher 5 year OS than did patients with LCL and PTCL.
According to the histopathological subtypes of NHL, treatment with the modified LMB protocol in patients with BL proved effective: the 5 year EFS was 88.5% AE 6.3%, which is consistent with the outcome of LMB-type protocols in previous studies. 5, 12, [20] [21] [22] [23] Patients with DLBCL had lower 5 year EFS than in previous studies. 12, [23] [24] [25] [26] [27] This might be due to the disappointing outcomes of the previously assigned RAMA-LCL protocol for DLBCL patients. Also, almost all patients with DLBCL had advanced disease with a high rate of CNS involvement at diagnosis. This contrasts with the literature, in which patients with DLBCL rarely had any CNS involvement, indicating the aggressiveness of DLBCL in the present cohort. We also showed that a modified LMB protocol was effective for patients with DLBCL, similar to studies that used the Pediatric Oncology Group and Berlin-Frankfurt-M€ unster (BFM)-90 protocols. 20, 21 Rituximab, an anti-CD20 monoclonal antibody, is approved for treatment of B-cell NHL in adults. The present outcomes were slightly superior to those in adult patients with a corresponding histology without rituximab. [28] [29] [30] At present, the treatment approach for pediatric advanced LBL involves ALL-based regimens. [31] [32] [33] The present 5 year EFS and OS rates for patients with LBL were lower than those in previous studies. 24, 27, 34, 35 This was due to the higher relapse rate in patients with localized LBL using CHOP regimens, and treatment-related complications. In previous studies, most of the pediatric patients with LBL presented with advanced disease. Thus, limited data were available regarding the optimal chemotherapeutic intensity and duration for localized LBL. This might imply the need for continuation therapy for localized LBL to prevent early relapse. Additionally, patients with relapse of LBL responded well and survived >10 years after re-induction and treatment with the RAMA-ALL protocol. An ALL-based protocol should thus be used for treatment of both localized and advanced LBL.
In the present study, the 5 year EFS rate for LCL was 65.2% AE 9.9%. In comparison, previous studies reported a 5 year EFS of 76% in those receiving short-pulse chemotherapy (BFM protocol) and of 72% in those who received extended chemotherapy (7-8 months for the French Pediatric Oncology Society protocol and 12 months for the Pediatric Oncology Group protocol). [36] [37] [38] [39] [40] The present outcome of treatment with the RAMA-LCL protocol was not excellent, but at least acceptable, without the use of an anthracycline such as daunorubicin and doxorubicin, which might be beneficial in the avoidance of cardiotoxicity-related side-effects in pediatric LCL. PTCL has a high prevalence in Asian children with NHL. 17 The outcome of PTCL is similar to that obtained by other groups using different regimens. [38] [39] [40] No standard chemotherapy regimen, however, has yet been developed for PTCL, and at the time of the study, a non-anthracycline protocol was used at the present institute. This inferior outcome of the RAMA-LCL protocol for LCL and PTCL might had been due to the chemotherapeutic doses used in the protocol. The role of intensified chemotherapy for LCL and PTCL should be explored.
The diagnosis of NHL was based on the histopathological characteristics; full-range immunologic and molecular genetic analyses were not routinely performed. This might be problematic in the subclassification of each of the NHL subtypes, especially LBL, only 40% of which are classified as T-or Bcell LBL. The pathological protocol was recently created to provide full-range immunologic studies for childhood NHL according to the WHO classification and was applicable to the risk stratification of newly diagnosed NHL at the present institute. Treatment abandonment was considered to be treatment failure, which strongly affects treatment outcomes in developing countries. No treatment abandonment occurred in the present series. Our multidisciplinary team and the Childhood Cancer Foundation, a local non-government organization, played a vital role in the delivery of cancer treatment to all patients and sought to provide families in need with parental support groups, transportation, housing, and supplementary medical-cost assistance.
In conclusion, the present cohort of patients with childhood NHL had a unique distribution across NHL subtypes with a high prevalence of LCL and PTCL. Most of the present patients were in the advanced stages of disease, especially patients with DLBCL who had CNS involvement. Our treatment stratification with an adapted protocol used in developed countries according to histological subtypes appears to be effective and has a low incidence of treatmentrelated complications. The modified LMB protocol is suitable for BL and DLBCL with excellent outcomes. The role of rituximab, however, should be further explored in pediatric BL and DLBCL in the future. Also, more intensified chemotherapy for LCL and PTCL need to be developed at the present institute.
